Mindset Pharma Inc. (CSE:MSET; FSE:9DF; OTCQB:MSSTF) has announced its intent to work with the Toronto-based Centre for Addiction and Mental Health (CAMH) on a preclinical study related to its lead asset, MSP-1014, a patented second-generation psilocybin-like compound.
The company plans on exploring the use of the serotonin 2A receptor agonist MSP-1014 as a treatment for anxiety and depressive disorders.
Mindset plans on testing MSP-1014 alongside psilocybin.
In the preclinical study involving rats, Mindset and CAMH will explore how macro and micro doses of psychedelic compounds affect expression levels of molecular biomarkers of brain plasticity.
Dr. Anh Dzung Lê, Senior Scientist and Head of Neurobiology of Alcohol Lab in the Campbell Family Mental Health Research Institute at CAMH, will lead the study. Dr. Douglas Funk, a project scientist in the CAMH Neurobiology of Alcohol Lab will offer support.
“Mindset’s drug discovery platform is built on a broad spectrum of high-quality scientific data generated in preclinical models. This collaboration will profile and build our understanding of the observed superiority of our lead asset, MSP-1014, to psilocybin at the molecular level. We are excited to partner with Dr Lê and Dr. Funk who are pioneers in mental health research to build this dataset and continue in our shared mission to advance groundbreaking new treatments to patients who are waiting.” said James Lanthier, CEO of Mindset, in a statement. “This study is the beginning of a strong partnership with CAMH, and we are excited for the research to come.”
Filed Under: Psychiatric/psychotropic drugs
